Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 852 participants.

Also called NCT06660719

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 852 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06660719
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06660719. Randomized; triple masking; primary purpose treatment. Start 2025-02-14 (actual); primary completion 2027-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care
Acronym
SP-8203-3001
Intervention (Drug)
SP-8203
Intervention (Drug)
Placebo
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06660719
Content hash
777c468295ef5222f689b1e15280dc3e5272325d45861e74258c78a94a50901d